HRP20160009T1 - Protutijela anti-cd37 - Google Patents
Protutijela anti-cd37 Download PDFInfo
- Publication number
- HRP20160009T1 HRP20160009T1 HRP20160009TT HRP20160009T HRP20160009T1 HR P20160009 T1 HRP20160009 T1 HR P20160009T1 HR P20160009T T HRP20160009T T HR P20160009TT HR P20160009 T HRP20160009 T HR P20160009T HR P20160009 T1 HRP20160009 T1 HR P20160009T1
- Authority
- HR
- Croatia
- Prior art keywords
- chain
- seq
- amino acid
- acid sequence
- weak
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 102000053602 DNA Human genes 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 8
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 102000048426 human CD37 Human genes 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (24)
1. Molekula kimernog protutijela, naznačena time, da se veže na ljudski CD37 i koja je definirana sa sljedećim:
(i) varijabilni jaki lanac koji sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO:2;
(ii) varijabilni slabi lanac koji sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO:4;
(iii) konstantni jaki i slabi lanci koji su izvorno ljudski.
2. Molekula protutijela prema zahtjevu 1, naznačena time, da:
(i) konstantni jaki lanac je IgG1-lanac, i
(ii) konstantni slabi lanac je kappa-lanac.
3. Molekula protutijela prema zahtjevu 1 ili 2, naznačena time, da navedena molekula protutijela ima jednu ili više mutacija u Fc-domeni, koje moduliraju jednu ili više djelotvornih funkcija, poželjno navedena modulacija djelotvorne funkcije je povećanje u citotoksičnosti posredstvom stanice koja je ovisna o protutijelu.
4. Molekula protutijela prema zahtjevu 3, naznačena time, da su navedene jedna ili više mutacija u Fc-domeni, kombinacija supstitucija na pozicijama 239 i 332, ili 236 i 332, ili 236, 239 i 332, numeriranima prema indeksu numeriranja Kabat EU, poželjno su navedene supstitucije sljedeće: I332E i S239D ili I332E i G236A, ili S239D, I332E i G236A.
5. Molekula protutijela prema bilo kojem od zahtjeva 1 do 4, naznačena time, da ona ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:28 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:30.
6. Molekula protutijela prema bilo kojem od zahtjeva 1 do 4, naznačena time, da ona ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:32 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:34.
7. Molekula protutijela prema bilo kojem od zahtjeva 1 do 4, naznačena time, da ona ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:24 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:26.
8. Protutijelo, naznačeno time, da se veže na ljudski CD37 i ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:28 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:30.
9. Protutijelo, naznačeno time, da se veže na ljudski CD37 i ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:32 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:34.
10. Protutijelo, naznačeno time, da se veže na ljudski CD37 i ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:24 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:26.
11. DNK-molekula, naznačena time, da obuhvaća područje koje kodira varijabilni jaki lanac od protutijela prema zahtjevima od 1 do 10, te područje koje kodira varijabilni slabi lanac od protutijela prema zahtjevima od 1 do 10.
12. DNK-molekula prema zahtjevu 11, naznačena time, da navedeno područje koje kodira varijabilni jaki lanac je staljeno na područje koje kodira konstantni jaki lanac iz ljudskog izvora, dok spomenuti ljudski konstantni jaki lanac je poželjno IgG1 i spomenuti ljudski konstantni jaki lanac poželjno ima jednu ili više supstitucija u Fc-području.
13. DNK-molekula prema zahtjevu 12, naznačena time, da navedeni IgG1 se kodira pomoću sekvence prikazane u SEQ ID NO:27 ili SEQ ID NO:31 ili SEQ ID NO:23.
14. DNK-molekula prema zahtjevu 11, naznačena time, da je navedeno područje koje kodira slabi lanac, staljeno na područje koje kodira konstantni slabi lanac iz ljudskog izvora, dok navedeni konstantni slabi lanac je poželjno kappa-lanac.
15. DNK-molekula prema zahtjevu 14, naznačena time, da se navedeni slabi kappa-lanac kodira pomoću sekvence prikazane u SEQ ID NO:29 ili SEQ ID NO:33 ili SEQ ID NO:25.
16. Vektor ekspresije, naznačen time, da obuhvaća molekulu DNK prema bilo kojem od zahtjeva 11 do 15, poželjno vektor obuhvaća molekulu DNK prema zahtjevu 13 i/ili molekulu DNK prema zahtjevu 15.
17. Stanica domaćina, naznačena time, da nosi jedan ili više vektora prema zahtjevu 16.
18. Postupak za proizvodnju protutijela prema bilo kojem od zahtjeva 1 do 10, naznačen time, da obuhvaća transfekciju stanice domaćina sisavca s jednim ili više vektora prema zahtjevu 16, kultiviranje stanice domaćina i obnavljanje i pročišćavanje molekule protutijela.
19. Farmaceutski sastav, naznačen time, da obuhvaća, kao djelatni sastojak, jednu ili više molekula protutijela anti-CD37, prema bilo kojem od zahtjeva 1 do 10, i farmaceutski prihvatljiv nosač.
20. Farmaceutski sastav prema zahtjevu 19, naznačen time, da nadalje obuhvaća jedno ili više terapeutskih sredstava.
21. Farmaceutski sastav prema zahtjevu 20, naznačen time, da navedeni jedno ili više terapeutskih sredstava su sredstva koja ciljaju na antigen CD20 od B-stanice.
22. Farmaceutski sastav prema zahtjevima od 19 do 21, naznačen time, da se upotrebljava u iscrpljivanju B-stanica koje izražavaju CD37 na svojoj površini.
23. Farmaceutski sastav prema zahtjevima od 19 do 21, naznačen time, da se upotrebljava za ozdravljenje B-stanica od malignih bolesti ili autoimunih bolesti ili upalnih bolesti, koje uključuju B-stanicu u njihovoj patologiji, a poželjno su maligne bolesti B-stanice odabrane od sljedećih: non-Hodgkin-limfom B-stanice, kronična limfocitna leukemija B-stanice i multipli mijelom.
24. Postupak za iscrpljivanje B-stanica koje izražavaju CD37 u populaciji stanica, naznačen time, da obuhvaća davanje, navedenoj populaciji stanica, molekule protutijela prema bilo kojem od zahtjeva 1 do 10, ili davanje farmaceutskog sastava koji obuhvaća takvu molekulu protutijela, pri čemu se navedeni postupak izvodi in vitro.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114128 | 2007-08-09 | ||
| EP08787055.6A EP2178915B1 (en) | 2007-08-09 | 2008-08-08 | Anti cd37 antibodies |
| PCT/EP2008/060464 WO2009019312A2 (en) | 2007-08-09 | 2008-08-08 | Anti cd37 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160009T1 true HRP20160009T1 (hr) | 2016-02-12 |
Family
ID=38925567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160009TT HRP20160009T1 (hr) | 2007-08-09 | 2016-01-05 | Protutijela anti-cd37 |
Country Status (37)
| Country | Link |
|---|---|
| US (7) | US20100189722A1 (hr) |
| EP (3) | EP2241577A1 (hr) |
| JP (3) | JP5325216B2 (hr) |
| KR (1) | KR101593403B1 (hr) |
| CN (4) | CN103396490A (hr) |
| AR (2) | AR071242A1 (hr) |
| AU (1) | AU2008285590B2 (hr) |
| BR (2) | BRPI0815369A2 (hr) |
| CA (1) | CA2693464C (hr) |
| CL (3) | CL2008002349A1 (hr) |
| CO (1) | CO6251371A2 (hr) |
| CY (1) | CY1117101T1 (hr) |
| DK (1) | DK2178915T3 (hr) |
| EA (2) | EA027499B1 (hr) |
| EC (2) | ECSP109946A (hr) |
| ES (1) | ES2555202T3 (hr) |
| HK (1) | HK1220708A1 (hr) |
| HR (1) | HRP20160009T1 (hr) |
| HU (1) | HUE026221T2 (hr) |
| IL (1) | IL202645A (hr) |
| MA (1) | MA32665B1 (hr) |
| ME (1) | ME02300B (hr) |
| MY (1) | MY157555A (hr) |
| NZ (2) | NZ600022A (hr) |
| PE (3) | PE20090499A1 (hr) |
| PH (1) | PH12014501812B1 (hr) |
| PL (1) | PL2178915T3 (hr) |
| PT (1) | PT2178915E (hr) |
| RS (1) | RS54359B1 (hr) |
| SG (1) | SG190657A1 (hr) |
| SI (1) | SI2178915T1 (hr) |
| TN (1) | TN2010000068A1 (hr) |
| TW (2) | TW201512220A (hr) |
| UA (2) | UA105445C2 (hr) |
| UY (1) | UY31275A1 (hr) |
| WO (1) | WO2009019312A2 (hr) |
| ZA (1) | ZA200908758B (hr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| PE20090499A1 (es) * | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| JP2010540460A (ja) * | 2007-09-24 | 2010-12-24 | トラガラ ファーマシューティカルズ，インク． | ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療 |
| CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
| EA027502B1 (ru) * | 2009-12-23 | 2017-08-31 | Зиниммуне Гмбх | Антитела против flt3 и способы их применения |
| NO331080B1 (no) | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| MY173839A (en) * | 2010-03-12 | 2020-02-24 | Debiopharm Int Sa | Cd37-binding molecules and immunoconjugates thereof |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20120107317A1 (en) * | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
| JP6018622B2 (ja) | 2011-04-01 | 2016-11-02 | イミュノジェン， インコーポレイテッド | Ｃｄ３７結合性分子及びその免疫複合体 |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| JP2015501654A (ja) * | 2011-12-13 | 2015-01-19 | ノルディック ナノベクター アーエス | 治療用キメラ型抗ｃｄ３７抗体ｈｈ１ |
| RU2014140119A (ru) * | 2012-03-30 | 2016-05-27 | Иммьюноджен, Инк. | Способы повышения эффективности терапии на основе cd37 |
| WO2013160396A1 (en) | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| US20130309224A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with rituximab |
| JP2015517511A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| WO2014151438A1 (en) * | 2013-03-15 | 2014-09-25 | Emergent Product Development Seattle, Llc | Multispecific anti-cd37 antibodies and related compositions and methods |
| WO2014198330A1 (en) * | 2013-06-14 | 2014-12-18 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with chlorambucil |
| TWI646108B (zh) | 2013-08-01 | 2019-01-01 | 艾澤西公司 | 結合至ｃｄ３７蛋白質之抗體藥物結合物（ａｄｃ） |
| US9291244B2 (en) | 2014-01-17 | 2016-03-22 | Ford Global Technologies, Llc | Nine speed automatic transmission |
| EP2966085A1 (en) | 2014-07-11 | 2016-01-13 | Boehringer Ingelheim International GmbH | Antibody IgG1 with a modified heavy chain constant region |
| CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| JP6979877B2 (ja) | 2015-06-08 | 2021-12-15 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ |
| EP3124976B1 (en) * | 2015-07-28 | 2018-09-12 | F. Hoffmann-La Roche AG | Improved bacterial endotoxin test for the determination of endotoxins |
| US11104740B2 (en) | 2015-08-28 | 2021-08-31 | Debiopharm International, S.A. | Antibodies and assays for detection of CD37 |
| CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| WO2018083633A1 (en) | 2016-11-02 | 2018-05-11 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| US11578115B2 (en) | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| CN110461363B (zh) | 2017-03-16 | 2024-04-02 | 综合医院公司 | 靶向cd37的嵌合抗原受体 |
| SG11201908772TA (en) | 2017-03-31 | 2019-10-30 | Genmab Holding B V | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| EP3644722A1 (en) | 2017-06-27 | 2020-05-06 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized asgr1 locus |
| US20210268027A1 (en) * | 2018-06-22 | 2021-09-02 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 and cd19 |
| EP3810194A1 (en) | 2018-06-22 | 2021-04-28 | Genmab Holding B.V. | Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof |
| JPWO2020004337A1 (ja) * | 2018-06-27 | 2021-08-02 | 国立大学法人東海国立大学機構 | Ｃｄ３７特異的キメラ抗原レセプター |
| KR20210116429A (ko) | 2018-10-04 | 2021-09-27 | 젠맵 홀딩 비.브이. | 이중특이적 항-cd37 항체를 포함하는 제약 조성물 |
| CN114650867A (zh) * | 2019-08-30 | 2022-06-21 | 齐鲁普吉湾生物治疗公司 | 抗cd20抗体、抗cd37抗体及它们的混合物 |
| WO2023057583A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| AU2022368385A1 (en) * | 2021-10-18 | 2024-04-11 | Daiichi Sankyo Company, Limited | Anti-cd37 antibody-drug conjugate |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8800077D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
| EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| WO1990002569A1 (en) * | 1988-09-06 | 1990-03-22 | International Genetic Engineering, Inc. | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| DE59010941D1 (de) | 1989-04-21 | 2005-03-24 | Amgen Inc | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| DE69232944T2 (de) | 1991-08-14 | 2003-12-24 | Genentech Inc | Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DK0701571T3 (da) | 1993-06-03 | 1997-09-15 | Therapeutic Antibodies Inc | Antistoffragmenter til terapi |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| JP2002505086A (ja) | 1998-02-25 | 2002-02-19 | レキシジェン ファーマシューティカルズ コーポレイション | 抗体ベースの融合タンパク質の循環半減期の増強 |
| DE19911329A1 (de) | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2388063C (en) | 1999-11-24 | 2010-06-08 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| WO2001049698A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| CN101914158A (zh) * | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
| AU2003259835A1 (en) | 2002-08-15 | 2004-03-03 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
| EP1562972B1 (en) | 2002-10-15 | 2010-09-08 | Facet Biotech Corporation | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| KR20060080535A (ko) | 2003-05-14 | 2006-07-10 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| KR100863776B1 (ko) | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 |
| WO2006031994A2 (en) | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| EP2325206B1 (en) | 2004-11-12 | 2014-03-19 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| AU2006299429B2 (en) * | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| RU2425841C2 (ru) | 2005-10-12 | 2011-08-10 | МорфоСис АГ | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| US20090148447A1 (en) | 2007-07-06 | 2009-06-11 | Trubion Pharmaceuticals, Inc. | Binding Peptides Having a C-terminally Disposed Specific Binding Domain |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
| UA108735C2 (uk) | 2008-07-21 | 2015-06-10 | Структурні варіанти антитіл для покращення терапевтичних характеристик | |
| JP2012508774A (ja) | 2008-11-13 | 2012-04-12 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | Ｃｄ３７免疫治療薬併用療法およびその使用 |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| WO2013160396A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| US20130309224A1 (en) * | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with rituximab |
| JP2015517511A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| WO2014198330A1 (en) | 2013-06-14 | 2014-12-18 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with chlorambucil |
-
2008
- 2008-08-07 PE PE2008001321A patent/PE20090499A1/es active IP Right Grant
- 2008-08-07 PE PE2011000972A patent/PE20120259A1/es active IP Right Grant
- 2008-08-07 PE PE2013000843A patent/PE20140196A1/es not_active Application Discontinuation
- 2008-08-08 AR ARP080103490A patent/AR071242A1/es not_active Application Discontinuation
- 2008-08-08 CL CL2008002349A patent/CL2008002349A1/es unknown
- 2008-08-08 PT PT87870556T patent/PT2178915E/pt unknown
- 2008-08-08 SG SG2013037619A patent/SG190657A1/en unknown
- 2008-08-08 EA EA201000274A patent/EA027499B1/ru not_active IP Right Cessation
- 2008-08-08 AU AU2008285590A patent/AU2008285590B2/en not_active Ceased
- 2008-08-08 HU HUE08787055A patent/HUE026221T2/en unknown
- 2008-08-08 RS RS20150817A patent/RS54359B1/en unknown
- 2008-08-08 EP EP10168244A patent/EP2241577A1/en not_active Withdrawn
- 2008-08-08 US US12/672,378 patent/US20100189722A1/en not_active Abandoned
- 2008-08-08 EP EP12185691.8A patent/EP2562187B1/en active Active
- 2008-08-08 NZ NZ600022A patent/NZ600022A/xx not_active IP Right Cessation
- 2008-08-08 DK DK08787055.6T patent/DK2178915T3/en active
- 2008-08-08 ES ES08787055.6T patent/ES2555202T3/es active Active
- 2008-08-08 PL PL08787055T patent/PL2178915T3/pl unknown
- 2008-08-08 CN CN2013102616193A patent/CN103396490A/zh active Pending
- 2008-08-08 BR BRPI0815369-8A patent/BRPI0815369A2/pt active Search and Examination
- 2008-08-08 EP EP08787055.6A patent/EP2178915B1/en active Active
- 2008-08-08 CN CN200880102642A patent/CN101815725A/zh active Pending
- 2008-08-08 KR KR1020107002636A patent/KR101593403B1/ko active IP Right Grant
- 2008-08-08 ME MEP-2015-191A patent/ME02300B/me unknown
- 2008-08-08 BR BRPI0823331-4A2A patent/BRPI0823331A2/pt not_active Application Discontinuation
- 2008-08-08 UA UAA201303569A patent/UA105445C2/uk unknown
- 2008-08-08 NZ NZ583713A patent/NZ583713A/en not_active IP Right Cessation
- 2008-08-08 UA UAA201002500A patent/UA103005C2/ru unknown
- 2008-08-08 MY MYPI2010000565A patent/MY157555A/en unknown
- 2008-08-08 TW TW103121994A patent/TW201512220A/zh unknown
- 2008-08-08 TW TW097130378A patent/TWI535733B/zh not_active IP Right Cessation
- 2008-08-08 SI SI200831544T patent/SI2178915T1/sl unknown
- 2008-08-08 EA EA201200994A patent/EA201200994A1/ru unknown
- 2008-08-08 CN CN201510756148.2A patent/CN105273086A/zh active Pending
- 2008-08-08 CA CA2693464A patent/CA2693464C/en not_active Expired - Fee Related
- 2008-08-08 UY UY31275A patent/UY31275A1/es not_active Application Discontinuation
- 2008-08-08 WO PCT/EP2008/060464 patent/WO2009019312A2/en active Application Filing
- 2008-08-08 JP JP2010519473A patent/JP5325216B2/ja active Active
- 2008-08-08 CN CN2011102205939A patent/CN102276724A/zh active Pending
-
2009
- 2009-12-09 ZA ZA200908758A patent/ZA200908758B/xx unknown
- 2009-12-10 IL IL202645A patent/IL202645A/en active IP Right Grant
-
2010
- 2010-02-08 TN TNP2010000068A patent/TN2010000068A1/fr unknown
- 2010-02-09 CO CO10014090A patent/CO6251371A2/es not_active Application Discontinuation
- 2010-02-09 MA MA32605A patent/MA32665B1/fr unknown
- 2010-02-09 EC EC2010009946A patent/ECSP109946A/es unknown
- 2010-08-18 JP JP2010183075A patent/JP5238000B2/ja active Active
- 2010-09-17 US US12/884,563 patent/US20110165153A1/en not_active Abandoned
- 2010-12-02 HK HK16108880.8A patent/HK1220708A1/zh unknown
-
2011
- 2011-06-24 CL CL2011001592A patent/CL2011001592A1/es unknown
- 2011-08-03 EC EC2011009946A patent/ECSP11009946A/es unknown
-
2012
- 2012-08-22 CL CL2012002329A patent/CL2012002329A1/es unknown
-
2013
- 2013-07-19 JP JP2013150731A patent/JP2014039541A/ja not_active Withdrawn
- 2013-08-23 US US13/974,230 patent/US20140004110A1/en not_active Abandoned
- 2013-08-23 US US13/974,226 patent/US9078879B2/en active Active
-
2014
- 2014-08-11 PH PH12014501812A patent/PH12014501812B1/en unknown
-
2015
- 2015-04-22 US US14/693,047 patent/US9932399B2/en active Active
-
2016
- 2016-01-05 HR HRP20160009TT patent/HRP20160009T1/hr unknown
- 2016-01-12 CY CY20161100025T patent/CY1117101T1/el unknown
-
2017
- 2017-03-16 AR ARP170100658A patent/AR107902A2/es unknown
-
2018
- 2018-02-15 US US15/897,400 patent/US20180186876A1/en not_active Abandoned
-
2020
- 2020-11-04 US US17/088,765 patent/US20210230271A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160009T1 (hr) | Protutijela anti-cd37 | |
| CA2994425C (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
| CN111263769B (zh) | Siglec-9中和性抗体 | |
| CN107532188B (zh) | Cd20结合分子及其用途 | |
| HRP20201001T1 (hr) | Metode za liječenje tumora pomoću cd3xcd20 bispecifičnog antitijela | |
| JP2022177090A5 (hr) | ||
| RU2406730C2 (ru) | Гуманизированное моноклональное анти-cd20-антитело | |
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| JP2017536829A5 (hr) | ||
| JP2018519263A5 (hr) | ||
| JP2018513149A5 (hr) | ||
| JP2018500014A5 (hr) | ||
| HRP20240149T1 (hr) | Bispecifična molekula za vezanje antigena, koji vežu cd3 i cd20, i njihove upotrebe | |
| HRP20220893T1 (hr) | Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor | |
| US11083785B2 (en) | Siglec-10 antibodies | |
| JP2017530119A (ja) | リンパ球における阻害経路の中和 | |
| AU2019452936A1 (en) | Bispecific antibody, preparation method therefor and application thereof | |
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| IL297847B1 (en) | Anti-PD-L1 antibody and its use | |
| US11447570B2 (en) | Binding unit targeting fibroblast activation protein α and application thereof | |
| JPWO2020018820A5 (hr) | ||
| JP2024050549A (ja) | 二重特異性ｔ細胞誘導体及びその使用 | |
| US11713357B2 (en) | CD38 protein antibody and application thereof | |
| CA3219336A1 (en) | Uses of anti-icos antibodies | |
| CN114106182A (zh) | 抗tigit的抗体及其用途 |